Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Di Loreto

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 1, 2022
Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in UmbriaChiara Di Loreto, Viviana Minarelli, Giovanni Nasini, et al.
Frontiers in Clinical Diabetes and Healthcare|May 29, 2024
Enhancing diabetes therapy adherence: a comprehensive study on glucometer usability for type 2 diabetes patientsGiovanni Toletti, Andrea Boaretto, Chiara Di Loreto, et al.
Acta Bio-Medica : Atenei Parmensis|August 22, 2006
Exercise and diabetesPierpaolo De Feo, Chiara Di Loreto, Anna Ranchelli, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 11, 2024
Effectiveness, Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes: A 4-Year Follow-Up Real-World StudyChiara Di Loreto, Roberta Celleno, Debora Pezzuto, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 22, 2024
Suitability and Usefulness of a Flexible Dosing Timing of Oral Semaglutide to Maximize Benefit in Clinical Practice: An Expert PanelRiccardo Candido, Chiara Di Loreto, Paolo Desenzani, et al.
Diabetes, Obesity & Metabolism|February 15, 2023
Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational studyRaffaele Napoli, Cesare Berra, Andrei-Mircea Catarig, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 11, 2019
Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and SafetyPaola Ponzani, Cesare Berra, Alessandra Di Lelio, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 23, 2018
Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and SafetyPaola Ponzani, Cesare Berra, Alessandra Di Lelio, et al.
Diabetes Care|January 28, 2003
Validation of a counseling strategy to promote the adoption and the maintenance of physical activity by type 2 diabetic subjectsChiara Di Loreto, Carmine Fanelli, Paola Lucidi, et al.
Diabetes|September 28, 2002
Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemiaPaola Lucidi, Giuseppe Murdolo, Chiara Di Loreto, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 1, 2022
Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in UmbriaChiara Di Loreto, Viviana Minarelli, Giovanni Nasini, et al.
Frontiers in Clinical Diabetes and Healthcare|May 29, 2024
Enhancing diabetes therapy adherence: a comprehensive study on glucometer usability for type 2 diabetes patientsGiovanni Toletti, Andrea Boaretto, Chiara Di Loreto, et al.
Acta Bio-Medica : Atenei Parmensis|August 22, 2006
Exercise and diabetesPierpaolo De Feo, Chiara Di Loreto, Anna Ranchelli, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 11, 2024
Effectiveness, Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes: A 4-Year Follow-Up Real-World StudyChiara Di Loreto, Roberta Celleno, Debora Pezzuto, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 22, 2024
Suitability and Usefulness of a Flexible Dosing Timing of Oral Semaglutide to Maximize Benefit in Clinical Practice: An Expert PanelRiccardo Candido, Chiara Di Loreto, Paolo Desenzani, et al.
Diabetes, Obesity & Metabolism|February 15, 2023
Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational studyRaffaele Napoli, Cesare Berra, Andrei-Mircea Catarig, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 11, 2019
Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and SafetyPaola Ponzani, Cesare Berra, Alessandra Di Lelio, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 23, 2018
Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and SafetyPaola Ponzani, Cesare Berra, Alessandra Di Lelio, et al.
Diabetes Care|January 28, 2003
Validation of a counseling strategy to promote the adoption and the maintenance of physical activity by type 2 diabetic subjectsChiara Di Loreto, Carmine Fanelli, Paola Lucidi, et al.
Diabetes|September 28, 2002
Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemiaPaola Lucidi, Giuseppe Murdolo, Chiara Di Loreto, et al.
Pageof 2